drugset / Trial / NCT01381445
A Study Assessing GW870086's Potential to Cause Skin Thinning
RandomizedCrossoverDouble-blindOther
Summary
This study is a randomised, double-blind, placebo-controlled study of topical GW870086 to explore the potential for skin thinning in healthy adult volunteers after 42±2 days of treatment. Twenty (20) healthy volunteers will be randomised to receive placebo and GW870086 2% cream, they will also receive either of the following treatments: GW870086 0.2% cream, or clobetasol propionate 0.05% cream.
Timeline
- Start
- 2011-04-14
- Primary completion
- 2011-07-07
- Completion
- 2011-07-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GW870086 | Small molecule | 0.2 % | Topical |
| Subject | GW870086 | Small molecule | 2 % | Topical |
| Subject | clobetasol propionate | Small molecule | 0.05 % | Topical |